Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves' Disease

Dr Simon Pearce, Professor of Endocrinology, Newcastle University, and Chief Investigator for the trial commented: "This is the first new therapy for Graves' disease to be tested in over 50 years and is a significant step forward in the development of the drug. We are very pleased to be leading the first clinical trial of ATX-GD-59 which has significant potential to treat the underlying cause of this condition for the first time."


I post previously about Newcastle university receiving £780,000 for research into Graves' Disease.


Last edited by

5 Replies

  • What wonderful news for those suffering Graves'. How completely awful that it's the first new therapy to be trialed for over fifty years. Make no mistake; misogyny is at the heart of what keeps so many thyroid patients ill. The poor men who also suffer are just collateral damage :(

    Perhaps Dr Pearce has a T shirt bearing the legend ' this is what a feminist looks like'. Rock on, doc :D

  • Have you got any more information about how this is supposed to work? What aspect of the disease does it act on?

  • Sorry, I should have put the link in! Have done so now.

    Apitope's ATX-GD-59 has the potential to treat and prevent the production of stimulating antibodies against TSHR (thyroid stimulating hormone receptor) that lead to Graves' disease. The Phase I trial will recruit up to 30 patients and is designed to assess the safety and initial efficacy of the product.

    It's a very small trail but it's a very small amount of money but it's still uplifting. :-)

  • No, not at the moment. He did say that it would be one tablet for several months rather than daily. People can contact them for more info.

  • Literally crying with happiness about this!!!!!!

You may also like...